Skip to main content

Table 1 Comparison of baseline clinicopathological characteristics based on PD-1 and PD-L1 expression of CRC patients in TCGA and FUSCC cohorts

From: Prognostic impact of programed cell death-1 (PD-1) and PD-ligand 1 (PD-L1) expression in cancer cells and tumor infiltrating lymphocytes in colorectal cancer

  TCGA Cohort (N = 356) FUSCC Cohort (N = 276)  
Cases PD-1 P a PD-L1 P a Cases PD-1 P a PD-L1 P a
No. (%) Low High   Low High   No. (%) Low High   Low High  
Age (years)
  ≤ 60 137 (38.5) 68 (41.2) 69 (36.1) 0.325 21 (38.2) 116 (38.5) 0.960 170 (61.6) 100 (58.8) 70 (66.0) 0.231 85 (61.6) 85 (61.6) 1.000
  > 60 219 (35.7) 97 (58.8) 122 (63.9)   34 (61.8) 185 (61.5)   106 (8.4) 70 (41.7) 36 (34.0)   53 (38.4) 53 (38.4)
Gender
 Male 199 (55.9) 91 (55.2) 108 (56.5) 0.792 33 (60.0) 166 (55.1) 0.505 166 (60.1) 102 (60.0) 64 (60.4) 0.950 88 (63.8) 78 (56.5) 0.219
 Female 157 (44.1) 74 (44.8) 83 (43.5)   22 (40.0) 135 (44.9)   110 (39.9) 68 (40.0) 42 (39.6)   50 (36.2) 60 (43.5)
Primary site
 Colon 269 (75.6) 115 (69.7) 154 (80.6) 0.017 46 (83.6) 223 (74.1) 0.130 129 (46.7) 84 (49.4) 45 (42.5) 0.260 65 (47.1) 64 (46.4) 0.904
 Rectum 87 (24.4) 50 (30.3) 37 (19.4)   9 (16.4) 78 (25.9)   147 (53.3) 86 (50.6) 61 (57.5)   73 (52.9) 74 (53.6)
Histological type
 Adenocarcinoma 316 (88.8) 149 (90.3) 167 (87.4) 0.393 50 (90.9) 266 (88.4) 0.584 261 (94.6) 158 (92.9) 103 (97.2) 0.132 132 (95.6) 129 (93.5) 0.426
 Mucinous/SRCC 40 (11.2) 16 (9.7) 24 (12.6)   5 (9.1) 35 (11.6)   15 (5.4) 12 (7.1) 3 (2.8)   6 (4.3) 9 (6.5)
T stage
 Tis-T2 68 (19.1) 29 (17.6) 39 (20.4) 0.386 9 (16.4) 78 (25.9) 0.844 43 (15.6) 24 (14.1) 19 (17.9) 0.588 19 (13.8) 24 (17.4) 0.044
 T3 242 (68.0) 118 (71.5) 124 (64.9)   39 (70.9) 203 (67.4)   32 (19.6) 32 (18.8) 22 (20.8)   20 (14.5) 34 (24.6)
 T4 46 (12.9) 18 (10.9) 28 (14.7)   7 (12.7) 39 (13.0)   179 (64.8) 114 (67.1) 65 (61.3)   99 (71.7) 80 (58.0)
N stage
 N0 194 (54.5) 83 (50.3) 111 (58.1) 0.185 23 (41.8) 171 (56.8) 0.101 120 (43.5) 70 (41.2) 50 (47.2) 0.432 57 (41.3) 63 (45.7) 0.767
 N1 98 (27.5) 53 (32.1) 45 (23.6)   18 (32.7) 80 (26.6)   83 (30.1) 49 (28.8) 33 (31.1)   43 (31.2) 40 (29.0)
 N2 64 (18.0) 29 (17.6) 35 (18.3)   14 (25.5) 50 (16.6)   73 (26.4) 50 (29.4) 23 (21.7)   38 (27.5) 35 (25.4)
M stage
 M0 245 (68.8) 109 (66.1) 136 (71.2) 0.107 34 (61.8) 211 (70.1) 0.284 234(84.8) 137 (80.6) 97 (91.5) 0.01 108(78.3) 126 (91.3) 0.003
 M1 48 (13.5) 29 (17.6) 19 (9.9)   11 (20.0) 37 (12.3)   42(15.2) 33 (19.4) 9 (8.5)   30(21.7) 12 (8.7)
 Mx 63 (17.7) 27 (16.4) 36 (18.8)   10 (18.2) 53 (17.6)        
Pathological grading
 Well/moderate NA 204(73.9) 67 (73.6) 137 (74.1) 0.498 102(73.9) 102 (73.9) 1.000
 Poor/anaplastic 56(20.3) 18 (19.8) 38 (20.5)   28(20.3) 28 (20.3)
 Unknown 16(5.8) 6 (6.6) 10 (5.4)   8(5.8) 8 (5.8)
Venous invasion
 Negative 235 (66.0) 105 (63.6) 130 (68.1) 0.557 28 (50.9) 207 (68.8) 0.026 184(66.7) 107 (62.9) 77 (72.6) 0.104 85(61.6) 99 (71.7) 0.193
 Positive 70 (19.7) 33 (20.0) 37 (19.4)   14 (25.5) 56 (18.6)   88(31.9) 59 (34.7) 29 (27.4)   51(37.0) 37 (26.8)
 Unknown 51 (14.3) 27 (16.4) 24 (12.6)   13 (23.6) 38 (12.6)   4(1.4) 4 (2.4) 0 (0.0)   2(1.4) 2 (1.4)
Nervous invasion
 Negative NA 231 (83.7) 75 (82.4) 156 (84.3) 0.181 118 (85.5) 231 (83.7) 0.337
 Positive 45 (16.3) 16 (17.6) 29 (15.7)   20 (14.5) 45 (16.3)
TILs extent
 Low 47 (13.2) 33 (20.0) 14 (7.3) 0.002 16 (29.1) 31 (10.3) <0.001 129 (46.7) 85 (50.0) 44 (41.5) 0.169 59 (42.8) 70 (50.7) 0.184
 High 93 (26.1) 42 (25.5) 51 (26.3)   17 (30.9) 76 (25.2)   147 (53.3) 85 (50.0) 62 (58.5)   79 (57.2) 68 (49.3)
 Unknown 216 (60.7) 90 (54.5) 126 (66.0)   22 (40.0) 194 (64.5)        
No. of LNs dissected
  < 12 80 (22.5) 42 (25.5) 38 (19.9) 0.219 14 (25.5) 56 (18.6) 0.658 39 (14.1) 24 (14.1) 15 (14.2) 0.994 16 (11.6) 23 (16.7) 0.226
  ≥ 12 247 (69.4) 107(64.8) 140 (73.3)   38 (69.1) 209 (69.4)   237 (85.9) 146 (85.9) 91 (85.8)   122 (88.4) 115 (83.3)
 Unknown 29 (8.1) 16 (9.7) 13 (6.8)   3 (5.5) 26 (8.6)        
MS status/MMR status
 MSS/MMR-proficient 243 (68.3) 123 (74.5) 120 (62.8) 0.018 39 (70.9) 204 (67.8) 0.646 176 (63.8) 102 (60.0) 74 (69.8) 0.099 93 (67.4) 83 (60.1) 0.21
 MSI/MMR-deficient 113 (31.7) 42 (25.5) 71 (37.2)   16 (29.1) 97 (32.2)   100 (36.2) 68 (40.0) 32 (30.2)   45 (32.6) 55 (39.9)
CEA (μl/ml)
  ≤ 5 144 (40.4) 59 (35.8) 85 (44.5) 0.151 13 (23.6) 131 (43.5) 0.007 170 (61.6) 106 (62.4) 64 (60.4) 0.532 80 (58.0) 90 (65.2) 0.382
  > 5 85 (23.9) 39 (23.6) 46 (24.1)   13 (23.6) 72 (23.9)   95 (34.4) 59 (34.7) 36 (34.0)   51 (37.0) 44 (31.9)
 Unknown 127 (35.7) 67 (40.6) 60 (31.4)   29 (52.7) 98 (32.6)   11 (4.0) 5 (2.9) 6 (5.7)   7 (5.1) 4 (2.9)
Adjuvant chemotherapy
 Yes NA 189 (68.5) 58 (63.7) 131 (70.8) 0.082 89 (64.5) 100 (72.5) 0.05
 No 49 (17.8) 15 (16.5) 34 (18.4)   23 (16.7) 26 (18.8)
 Unknown 38 (13.7) 18 (19.8) 20 (10.8)   26 (18.8) 12 (8.7)
  1. aItalic entries indicate statistical significance